LINZESS has a well-established safety profile among CIC patients1

LINZESS 145 mcg and 72 mcg were evaluated in 3 phase 3 placebo-controlled safety trials involving more than 850 adults with chronic idiopathic constipation (CIC)

chronic idiopathic constipation LINZESS safety adverse reactions

*“Abdominal pain” term includes the preferred terms: abdominal pain, upper abdominal pain, and lower abdominal pain.

  • In Trial 5, adverse reactions that occurred at a frequency of ≥2% in LINZESS 72 mcg–treated patients (n=411) and at a higher rate than placebo (n=401) were:
    • Diarrhea (LINZESS 72 mcg, 19%; LINZESS 145 mcg, 22%; placebo 7%)
    • Abdominal distension (LINZESS 72 mcg, 2%; LINZESS 145 mcg, 1%; placebo <1%)

Diarrhea was the most commonly reported adverse reaction of LINZESS1

  • In Trials 3, 4, and 5, 2% of the patients treated with 145 mcg LINZESS experienced severe diarrhea vs less than 1% in patients receiving placebo

The most common adverse reaction is diarrhea, which may appear in the first 2 weeks of treatment